What is the 13F Pro Quality Score for IRMD?

13F Pro ranks IRADIMED CORP (IRMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IRMD's current score at https://13fpro.ai/research/IRMD (free sign-up required for the full ranking).

Where does 13F Pro source IRMD data?

All IRADIMED CORP fundamentals and ownership data come directly from SEC EDGAR. IRADIMED CORP files with the SEC under CIK 1325618. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IRMD in?

IRADIMED CORP (IRMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are IRMD's largest expenses?

IRADIMED CORP's latest 10-Q reports these as the largest expense items: Cost of Revenue ($5.2M, +11% YoY); General and Administrative ($4.6M, —); Research and Development ($957K, +67% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2026 (quarter ended March 31, 2026).

How often is IRMD research updated on 13F Pro?

IRMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IRADIMED CORP(IRMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1325618 IRMD stock profile & AI dashboard →

13F Pro Quality Score

68.4/100

Rank #416 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

70.5/100

Profitability

87.5/100

Balance Sheet

96.7/100

Earnings Quality

61.2/100

Free Cash Flow

81.2/100

Institutional Flow

62.5/100

Revenue Scale

15.4/100

Dilution Risk

31.4/100

IRMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IRADIMED CORP (IRMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRMD at 68.4/100 on a 32-signal composite quality model, placing it at rank #416 of 2,879 stocks — the top 25% of the AI-ranked universe. IRMD scores in the top quartile across balance sheet strength (96.7), profitability (87.5), free cash flow (81.2). Areas of concern include revenue scale (15.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), IRADIMED CORP reports quarterly revenue of $22.0M, net income of $5.8M, an operating margin of 32.9%. Top institutional holders of IRMD by reported 13-F value include BlackRock,, RENAISSANCE TECHNOLOGIES, Copeland Capital Management,, based on the most recent SEC filings. IRMD trades on the Nasdaq exchange and files with the SEC under CIK 1325618. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IRADIMED CORP directly from SEC EDGAR. IRADIMED CORP's 13F Pro composite quality score has ranged between 8 and 81 since 2021, currently 68.4 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about IRADIMED CORP

Quirks, history, and lore behind IRMD — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. medical device company · listed on Nasdaq · headquartered in Florida.
2
The Numbers
Annual revenue in the range of $50–60 million — tiny by Wall Street standards, yet it commands a niche monopoly with enviable margins for its sector.
3
The History
Founded in the 2000s, the company carved out its entire business around one very specific engineering problem: keeping patients safe and monitored inside a machine that hates metal.
4
The Secret
Its flagship product is a non-magnetic IV infusion pump — designed from the ground up to work inside an MRI scanner without turning into a projectile.
5
The Lore
Standard IV pumps are banned from the MRI room; this company essentially owns that gap, making it the go-to vendor for hospitals that want to infuse drugs during an MRI procedure.
6
The Giveaway
The ticker is practically a confession: IR for intra-radiology, MED for medical — a Florida firm that built a business on the one pump that won't fly across the room when the magnets turn on.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving IRMD's Business? Latest 10-Q Breakdown

✓ 23/23 datapoints verified

AI-extracted from IRADIMED CORP's 10-Q filed 2026-05-01 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

IRMD revenue grew 13% YoY to $22.0M in Q1 2026, driven by continued strength in IV infusion pump systems ($7.7M, +28% YoY) and vital signs monitoring systems; net income increased 24% to $5.8M ($0.45/diluted share).

Biggest Revenue Drivers

Total revenue: $22.0M+13% YoY

Device Revenue$15.4M+19% YoY

Continued demand for IV infusion pump systems and modifications to sales incentive plan for patient vital signs monitoring systems.

Within Device Revenue

MRI Compatible IV Infusion Pump Systems$7.7M+28% YoY

MRI Compatible Patient Vital Signs Monitoring Systems$7.1M+9% YoY

Disposables$4.9M—

Revenue remained constant.

Amortization of Extended Maintenance Agreements$659K+18% YoY

Largest Expense Items

Cost of Revenue$5.2M+11% YoY

Increased proportionally with higher revenue.

General and Administrative$4.6M—

Remained consistent compared to prior year.

Research and Development$957K+67% YoY

Increase due to payroll and benefit expenses; prior year payroll was capitalized for MRidium 3870 development.

Sales and Marketing$4.1M-3% YoY

Reduced sales commissions related to timing and transition of sales focus to MRidium 3870 IV infusion pump system.

Margins: Gross profit margin improved to 77% in Q1 2026 from 76% in Q1 2025, while gross profit dollars increased 13% to $16.8M, demonstrating operational leverage as revenue scaled faster than cost of revenue growth (11%).

Watch Items from the Filing

U.S. represents 82% of revenue ($18.0M), creating geographic concentration risk; however, international revenue grew to $4.0M (+11% YoY).
Company evaluating tariff refund eligibility following February 2026 Supreme Court ruling; timing, process, and realization of refunds remain uncertain with no reasonable estimate possible.
Sole-source supplier dependencies noted for key components essential to product functionality; any disruption would have materially adverse impact.
Operating expenses as percentage of revenue improved to 43.6% from 48.2% YoY, reflecting operating leverage and improved cost management.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$22.0M

Net Income

Q1 2026

$5.8M

Free Cash Flow

Q1 2026

$7.9M

Operating Margin

Q1 2026

32.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+14.4% YoY

$83.8MFY 2025

FY20 $31.7MFY21 $41.8MFY24 $73.2MFY25 $83.8M

Net Income

+16.9% YoY

$22.5MFY 2025

FY20 $1.4MFY21 $9.3MFY24 $19.2MFY25 $22.5M

Operating Income

+19.0% YoY

$26.1MFY 2025

FY20 $-756.1KFY21 $9.8MFY24 $22.0MFY25 $26.1M

EPS (Diluted)

+16.7% YoY

$1.75FY 2025

FY20 $0.11FY21 $0.74FY24 $1.50FY25 $1.75

Total Assets

+10.6% YoY

$108.8MFY 2025

FY20 $71.1MFY21 $82.9MFY24 $98.3MFY25 $108.8M

Op. Cash Flow

-2.6% YoY

$24.9MFY 2025

FY20 $5.8MFY21 $11.3MFY24 $25.6MFY25 $24.9M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2016
Revenue	$83.8M +14.4%	$73.2M +75.2%	$41.8M +31.8%	$31.7M -17.7%	$38.5M +18.5%	$32.5M
Net Income	$22.5M +16.9%	$19.2M +106.3%	$9.3M +581.2%	$1.4M -85.8%	$9.6M +33.5%	$7.2M
Operating Income	$26.1M +19.0%	$22.0M +123.7%	$9.8M +1398.5%	$-756.1K -108.7%	$8.6M -20.8%	$10.9M
EPS (Diluted)	$1.75 +16.7%	$1.50 +102.7%	$0.74 +572.7%	$0.11 -85.9%	$0.78 +30.0%	$0.60
Total Assets	$108.8M +10.6%	$98.3M +18.6%	$82.9M +16.6%	$71.1M +6.5%	$66.7M +79.4%	$37.2M
Operating Cash Flow	$24.9M -2.6%	$25.6M +127.6%	$11.3M +93.5%	$5.8M -43.1%	$10.2M +8.8%	$9.4M

AI Insight: IRMD Financial Trends

IRMD delivers steady revenue growth from $18M to $22M over eight quarters while maintaining a debt-free balance sheet and expanding equity to $99M.

• Revenue grew 22% from $18M in Q2 2024 to $22M in Q1 2026, reflecting consistent top-line momentum.

• Equity expanded from $80M in Q2 2024 to $99M in Q1 2026 with zero reported debt throughout the period.

• Operating income improved from $6M in Q2 2024 to $7M in Q2 2025, holding steady through Q1 2026.

• Operating CF fluctuated between $4M and $9M quarter-to-quarter, showing no clear directional trend.

⚠ Equity dipped from $98M in Q3 2025 to $95M in Q4 2025 before recovering — first sequential decline in the series.

⚠ Revenue slipped from $23M in Q4 2025 to $22M in Q1 2026; monitor whether Q4 2025 was a seasonal peak.

⚠ Operating CF of $4M in Q1 2025 was the weakest reading — watch for similar seasonal pressure in Q1 2026 reporting.

AI Insight: IRMD Ratio Trends

IRADIMED's profitability recovered sharply after a Q1 2025 dip, with ROIC rebounding to 29.4% in Q1 2026 — near multi-period highs.

• Operating margin dipped to 27.8% in Q1 2025 but rebounded to 32.9% in Q1 2026, recovering above Q2 2024 levels of 31.4%.

• ROIC troughed at 24.1% in Q1 2025, then expanded to 30.0% in Q4 2025 and held at 29.4% in Q1 2026.

• ROA followed a similar arc: falling to 18.4% in Q1 2025, recovering to 23.7% in Q4 2025, then moderating to 20.3% in Q1 2026.

• D/E ratio is absent across all periods, limiting leverage assessment entirely.

⚠ Q1 2026 NPM of 26.5% lags Q4 2025's 28.4% — seasonal or cost pressure worth monitoring across coming quarters.

⚠ Q1 has been the weakest margin quarter in both 2025 and prior periods — confirm whether Q1 seasonality is structural.

Get alerted when IRMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IRADIMED CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IRMD

BlackRock, Inc.
$93.2M967,787 sh
RENAISSANCE TECHNOLOGIES LLC
$42.4M440,712 sh
Copeland Capital Management, LLC
$34.6M359,325 sh
VANGUARD CAPITAL MANAGEMENT LLC
$34.5M358,620 sh
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
$33.6M349,316 sh
Nine Ten Capital Management LLC
$32.2M334,488 sh
GEODE CAPITAL MANAGEMENT, LLC
$27.6M286,563 sh
DIMENSIONAL FUND ADVISORS LP
$21.8M226,146 sh
STATE STREET CORP
$19.7M204,528 sh
GOLDMAN SACHS GROUP INC
$19.1M197,945 sh

Fund	Value	Shares
BlackRock, Inc.	$93.2M	967,787
RENAISSANCE TECHNOLOGIES LLC	$42.4M	440,712
Copeland Capital Management, LLC	$34.6M	359,325
VANGUARD CAPITAL MANAGEMENT LLC	$34.5M	358,620
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC	$33.6M	349,316
Nine Ten Capital Management LLC	$32.2M	334,488
GEODE CAPITAL MANAGEMENT, LLC	$27.6M	286,563
DIMENSIONAL FUND ADVISORS LP	$21.8M	226,146
STATE STREET CORP	$19.7M	204,528
GOLDMAN SACHS GROUP INC	$19.1M	197,945

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IRMD on your watchlist

Track score changes the day IRADIMED CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IRMD a good stock to buy?

13F Pro's AI-powered analysis of IRADIMED CORP (IRMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IRMD are available on the IRMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IRMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IRMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IRADIMED CORP's investment landscape.